Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ... Science 340 (6132), 622-626, 2013 | 953 | 2013 |
Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains B DeLaBarre, AT Brunger Nature Structural & Molecular Biology 10 (10), 856-863, 2003 | 462 | 2003 |
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ... Cancer discovery 7 (5), 478-493, 2017 | 438 | 2017 |
Central pore residues mediate the p97/VCP activity required for ERAD B DeLaBarre, JC Christianson, RR Kopito, AT Brunger Molecular cell 22 (4), 451-462, 2006 | 268 | 2006 |
Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle I Rouiller, B DeLaBarre, AP May, WI Weis, AT Brunger, RA Milligan, ... Nature structural biology 9 (12), 950-957, 2002 | 253 | 2002 |
Nucleotide dependent motion and mechanism of action of p97/VCP B DeLaBarre, AT Brunger Journal of molecular biology 347 (2), 437-452, 2005 | 208 | 2005 |
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy C Kung, J Hixon, S Choe, K Marks, S Gross, E Murphy, B DeLaBarre, ... Chemistry & biology 19 (9), 1187-1198, 2012 | 195 | 2012 |
Full-length human glutaminase in complex with an allosteric inhibitor B DeLaBarre, S Gross, C Fang, Y Gao, A Jha, F Jiang, J Song J, W Wei, ... Biochemistry 50 (50), 10764-10770, 2011 | 167 | 2011 |
An allosteric mechanism for potent inhibition of human ATP-citrate lyase J Wei, S Leit, J Kuai, E Therrien, S Rafi, HJ Harwood Jr, B DeLaBarre, ... Nature 568 (7753), 566-570, 2019 | 129 | 2019 |
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency C Kung, J Hixon, PA Kosinski, G Cianchetta, G Histen, Y Chen, C Hill, ... Blood, The Journal of the American Society of Hematology 130 (11), 1347-1356, 2017 | 108 | 2017 |
NSF and p97/VCP: similar at first, different at last AT Brunger, B DeLaBarre FEBS letters 555 (1), 126-133, 2003 | 100 | 2003 |
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1 MI Davis, S Gross, M Shen, KS Straley, R Pragani, WA Lea, ... Journal of Biological Chemistry 289 (20), 13717-13725, 2014 | 97 | 2014 |
Considerations for the refinement of low-resolution crystal structures B DeLaBarre, AT Brunger Acta Crystallographica Section D: Biological Crystallography 62 (8), 923-932, 2006 | 97 | 2006 |
Action at a distance: allostery and the development of drugs to target cancer cell metabolism B DeLaBarre, J Hurov, G Cianchetta, S Murray, L Dang Chemistry & biology 21 (9), 1143-1161, 2014 | 92 | 2014 |
Therapeutically active compounds and their methods of use G Cianchetta, B Delabarre, J Popovici-Muller, FG Salituro, JO Saunders, ... US Patent 9,732,062, 2017 | 73 | 2017 |
X-ray structure determination at low resolution AT Brunger, B DeLaBarre, JM Davies, WI Weis Acta Crystallographica Section D: Biological Crystallography 65 (2), 128-133, 2009 | 63 | 2009 |
Crystal structures of homoserine dehydrogenase suggest a novel catalytic mechanism for oxidoreductases B DeLaBarre, PR Thompson, GD Wright, AM Berghuis nature structural biology 7 (3), 238-244, 2000 | 62 | 2000 |
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion Z Konteatis, J Travins, S Gross, K Marjon, A Barnett, E Mandley, B Nicolay, ... Journal of Medicinal Chemistry 64 (8), 4430-4449, 2021 | 53 | 2021 |
Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition DB Ulanet, K Couto, A Jha, S Choe, A Wang, HK Woo, M Steadman, ... PLoS One 9 (12), e115144, 2014 | 53 | 2014 |
Bi-specific fusion proteins U Nielsen, T Wickham, B Schoeberl, B Harms, B Linggi, M Onsum, ... US Patent 9,238,080, 2016 | 40 | 2016 |